SCHEMBL24254486

SCHEMBL24254486

CN(C)Sc1cccc(NC(=O)Cc2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.62
MEN1 O00255 1/20 0.62
SMN1; SMN2 Q16637 2/20 0.54
CFD P00746 1/20 0.52
RORC P51449 1/20 0.50
USP2 O75604 1/20 0.50
WNT3A P56704 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 1/20 0.50
MCHR1 Q99705 1/20 0.50
STAT3 P40763 1/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
EPHX2 P34913 1/20 0.49
NLRP3 Q96P20 1/20 0.48
LMNA P02545 2/20 0.47
NPC1 O15118 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254547 0.82 MEN1 (0.58) KMT2AMEN1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL24027877 0.79 MEN1 (0.54) KMT2AMEN1ALDH1A1LMNA
SCHEMBL3714852 0.78 KMT2A (1.00) KMT2AMEN1SMN1; SMN2CFDRORC
SCHEMBL24254476 0.77 KCNJ6 (0.77) KMT2AMEN1RORCWNT3AALDH1A1
SCHEMBL6098738 0.77 CFD (0.81) KMT2AMEN1SMN1; SMN2CFDUSP2
SCHEMBL1948079 0.77 KMT2A (0.83) KMT2AMEN1CFDRORCWNT3A
SCHEMBL253845 0.77 KMT2A (0.72) KMT2AMEN1SMN1; SMN2CFDRORC
SCHEMBL4300884 0.77 KMT2A (0.72) KMT2AMEN1SMN1; SMN2CFDRORC
SCHEMBL21242060 0.76 F2R (0.50) KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL4298937 0.75 ALDH1A1 (0.65) KMT2AMEN1SMN1; SMN2CFDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed